Immuno-Oncology Business Development and Strategic Alliances

NanoString Technologies
Job Location
530 Fairview Ave N
Seattle, WA 98109
Competitive Comp Package

NanoString offers a competitive benefits package including salary, bonus, stock options, ESPP, H/D/V, Life Insurance, Wellness Reimbursement and more.

Relocation assistance available.

Job Description

Reporting to the Senior Vice President of Corporate and Business Development, the Immuno-Oncology Business Development & Strategic Alliances role will serve as a key member of the Corporate and Business Development team, working closely with cross functional partners and the executive management team to drive and implement the Immuno-Oncology strategy.

Working with members of the cross-functional team, this position will play a leading role in shaping and refining the Immuno-Oncology strategic plan, will be the point person to coordinate company-wide activity related to Immuno-Oncology and will nurture relationships & manage the subsequent business development process / alliance management with academia, biopharmaceutical companies, associations and institutions. 

Major duties and responsibilities include:

  • Coordinate company-wide activity related to Immuno-Oncology.
  • In conjunction with team, develop and refine the strategic plan to capitalize on the immuno-oncology opportunity, including the research and diagnostic product roadmap and partnering approach.
  • Develop an understanding of the relevant disease biology, influential KOLs, disease management, new and emerging tools & diagnostics and new and emerging therapeutics in the field of Immuno-Oncology.
  • Identify, develop and nurture scientific and business IO relationships within academia, biopharmaceutical companies, associations, institutions and other stakeholders.
  • In conjunction with evaluation team, prioritize and access best-in-class IO content as basis for new research use only products and diagnostic assays.
  • Enter value-creating IO collaborations with premiere biopharmaceutical companies and leading KOLs/academics by applying best-practices across the business development process including:
  • Discover and prioritize potential collaboration opportunities by actively prospecting, collaborating with cross-functional partners and leveraging your network.
  • Oversee and conduct robust analysis and due diligence to uncover and advance the highest potential opportunities.
  • Construct innovative, value-creating “win-win” deals to meet strategic and financial goals, and effectively negotiate successful outcomes.
  • Develop and champion the business case and strategic rationale with Senior Management.
  • Take a leadership role in driving IO collaboration implementation.
  • Be a proactive and inspirational advocate for NanoString. Establish and build IO network to generate NanoString visibility and leadership.
  • Core contributor to Corporate & Business Development team to ensure individual and departmental goals are achieved by providing leadership, team support and driving other key initiatives.
  • Minimum of advanced degree in science or medicine; MBA preferred.
  • Energetic, resourceful self-starter with high integrity, strong executive presence and the ability to work effectively in a dynamic, entrepreneurial environment.
  • Excellent analytical, project management and organizational skills with the ability to make sound business judgments.
  • Solid network with demonstrated capability to build and maintain trusted relationships with shared vision and commitment to action.
  • Track record of driving from inception to execution including valuation, diligence, deal engineering and leading negotiations with particular emphasis with pursuing and closing “sell side” value-creating deals with biopharmaceutical companies.
  • Strong scientific, technical and business acumen in oncology (including solid tumors & hematological within immuno-oncology), personalized medicine, therapeutics and molecular diagnostics.
  • A strategic thinker with outstanding business instincts who can help chart the course and translate into actionable, value-creating results for the company.
  • An ability to embrace teamwork and collaboration.
  • Ability and willingness to travel.
About Our Organization

NanoString Technologies (NASDAQ:“NSTG”) provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in over 800 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation.  

The company's technology has now been applied to diagnostic use. The Prosigna Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. Leveraging the company’s innovative platform and proven development, regulatory and commercial expertise, NanoString has established a companion diagnostics capability to enable biopharmaceuticals partners to translate biomarker discoveries into clinically-relevant diagnostics, helping to bring the right therapy to the right patient at the right time. In 2014, NanoString entered into a collaboration with Celgene Corporation to develop a companion diagnostic assay using the nCounter® Analysis System to support the clinical validation of REVLIMID® for treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Under the terms of the collaboration agreement, NanoString is developing and commercializing the diagnostic test.

A strategic priority for NanoString is to expand its presence in the burgeoning field of immuno-oncology. In 2014, NanoString announced the introduction of a new highly multiplexed gene expression panel for the nCounter®Analysis System, the PanCancer Immune Profiling Panel. This novel panel enables researchers to create profiles of the human immune response in all cancer types, potentially accelerating the discovery and development of drugs, therapies and predictive biomarker signatures for immunotherapy treatment response. NanoString's PanCancer Immune Profiling Panel is designed to provide researchers with a novel tool to help facilitate new advancements in key research areas including targeting of checkpoint blockades, development of chimeric antigen receptors (CARs) for T-cell therapy, and the identification of adjuvants for stimulating the immune response in the tumor microenvironment.

In April of 2015, NanoString announced a multi-year collaboration with MD Anderson Cancer Center to accelerate the development and adoption of a revolutionary new type of assay based on NanoString's nCounter® Analysis System. The collaboration will involve the development of "multi-omic" assays, which simultaneously profile both gene and protein expression, with a primary focus on identifying important biomarkers in immuno-oncology as well as extending programs for targeting therapeutics. Further, the company will introduce new research panels for the simultaneous measurement of gene and protein expression, with the early access launch of the first panel at the American Association for Cancer Research (AACR) Annual Meeting in April 2015. This new capability has generated significant interest with biopharmaceutical partners as they seek new solutions to advance their therapeutic programs.

In May of 2015, The Cancer Immunotherapy Trials Network (CITN) and NanoString announced a multi-year translational research collaboration to discover biomarkers that predict clinical outcomes for cancer immunotherapies, both as single agents and in combination.

Later that month, MERCK and NanoString announced a clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in multiple tumor types. The collaboration will utilize NanoString's nCounter® Analysis System to optimize gene expression signatures as part of the clinical development program for KEYTRUDA.

New study finds bias against female lecturers among student course evaluations, the Economist reports.

A research duo finds that science and technology graduate students who turn away from academic careers do so because of changes in their own interests.

Students whose classmates are interested in science are more likely to think about a career in science, technology, engineering, and mathematics, a new study says.

CNBC reports that the genetic counseling field is expected to grow as personalized medicine becomes more common.